Hold on to that. When you go up there for service, you got to bring them that ticket. If you don't have >> Brad Sands, a former paramedic, is a RAM clinic coordinator.I'm number four. >> Number four, head owner. Who are the people in the cars.Everybody. I mean, it's your neighbors. It's your parents. It's It's your friends. It's the community around you.It's everybody. And it's nationwide. Somewhere in America, Brad Sands sets up a clinic like this most every weekend.It's all comers. Mhm. No questions asked ...

看護師さん向けに、え、こういった ショート動画で、えっと、教育するような 、えっと、歴の動画を流しております。 知識をこういきなりこう伝え るっていうのをすると、やっぱりちょっと 難しいなとか、ちょっと見るの嫌だなって いうところで、あんまりこう見ていただけ ない瞬間って結構あるんですね。なので 私たちは特にやっているのが看護師さん、 特に若手の看護師さんって結構上の先輩 から注意されたりするんですね。そうする とちょっと怖いなっていうような後輩の 様子をこう演じながら、あ、私もね、 ちょっとこんなちょっと聞かれるんじゃ ないか。聞かれたらやだなっていうところ でまず共感を得ながら、え、皆さんに レクチャーをしております。怒られる要素 こう演じしているなんて言ったんですけど ね。ま、ほとんど私の若い頃そのまんま やってるような感じです。で、あの、当時 の先輩にこういうの見られたら嫌だなと 思ったんですけれども、この間、えっと、 たまたま会いまして、星野君、私そんなに 厳しかったかな. っていう風に言われた時 はちょっとお腹が痛くなりました。え、私 元々IUの看護師をしてみました。たいっ ていうことだったり、専 ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $87.2 million, aligning with the midpoint of revised guidance, while full-year revenue reached $346.8 million, a 1.4% increase over 2024 [5][30] - Adjusted EBITDA for Q4 was $19.2 million, representing a margin expansion to 22%, and for the full year, it was $68.7 million, up 23% year-over-year [5][29][31] - Free cash flow for the year was $20 million, an increase of $5 million over 2024 [5][20] Business Line Data and Key Metrics Changes - Financial Health revenue totaled $221.7 million, up 2% year-over-year, while Patient Care revenue was $125.2 million, roughly flat compared to the prior year [30][28] - Bookings for Q4 were $19.8 million, up from $15.5 million sequentially and $14.3 million a year ago, indicating strong demand [6][25] - The percentage of recurring deals in the pipeline increased to over 70%, up from approximately 57% last summer [8] Market Data and Key Metrics Changes - The overall sales pipeline value is the highest it has been in nine quarters, increasing 53% since the beginning of Q3 [7] - The pipeline for opportunities greater than 100 beds has grown from 14% to 30% [7] Company Strategy and Development Direction - The company is engaged in a strategic review process to maximize shareholder value and is not issuing formal guidance for the time being [4] - A focus on AI strategy spans financial health, patient care, customer service, and internal development, with initiatives aimed at improving claims processing and customer interactions [12][15] - The company is committed to enhancing operational efficiency through technology and process improvements, particularly in the context of its global workforce transition [10][11] Management's Comments on Operating Environment and Future Outlook - Management anticipates modest revenue growth in 2026 and expects approximately 200 basis points of improvement in Adjusted EBITDA margins [4][33] - The company acknowledges challenges in customer retention but is implementing measures to improve the transition process and customer satisfaction [9][38] Other Important Information - The company has reduced net debt by approximately $19.5 million year-to-date, improving its net leverage ratio to 2x [21][32] - A new credit agreement was entered into, providing up to $250 million in credit facilities, enhancing liquidity and supporting strategic priorities [23] Q&A Session Summary Question: Can you explain the outlook for the year regarding modest revenue growth and the new bookings metric? - Management confirmed that recurring revenues and bookings at conversion are key to understanding visibility, with a focus on attrition and bookings translating into revenue [35][36] Question: How is customer retention improving, and what are the renewal numbers for 2025? - Management indicated that retention rates are not significantly improving, with a modest outlook for renewals in 2026 compared to 2025 [38] Question: What is the timeline for the strategic review process? - Management stated there is no specific timeline for the strategic review, emphasizing the importance of achieving the right outcome over meeting deadlines [41] Question: How should we think about the conversion timing of larger deals in the pipeline? - Management noted that there are no capacity constraints, but the timing of bookings is often dependent on customer readiness [45][47] Question: What are the expected impacts of the Rural Health Fund on customer bases? - Management is actively engaging with hospitals to help them access the $50 billion fund, viewing it as a significant opportunity [82][83] Question: How is AI being deployed in the company, and what is the competitive landscape? - Management has not observed significant changes in the competitive landscape but is focused on ensuring that AI projects deliver a return on investment [86][90]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $87.2 million, aligning with the midpoint of revised guidance, while full-year revenue reached $346.8 million, a 1.4% increase over 2024 [3][4] - Adjusted EBITDA for Q4 was $19.2 million, representing a margin expansion to 22%, up from 20.4% in Q4 2024, while full-year Adjusted EBITDA was $68.7 million, a 23% year-over-year increase [4][19] - Free cash flow for the year was $20 million, an increase of $5 million over 2024, with cash flow from operations rising to $37 million, a 19% increase year-over-year [4][15] Business Line Data and Key Metrics Changes - Financial Health revenue totaled $56.2 million in Q4, a 2% year-over-year increase, while Patient Care revenue was $31 million, reflecting a 6.6% decline primarily due to the sunset of the Centriq product [18][19] - Bookings for Q4 were $19.8 million, up $6 million year-over-year, supported by growing SaaS and strategic partnerships, with total bookings for the year at $82.9 million, a 1% increase [4][20] Market Data and Key Metrics Changes - The overall sales pipeline value is at its highest in nine quarters, increasing by 53% since the beginning of Q3, with a notable shift towards larger opportunities and recurring deals [5][6] - The percentage of recurring deals in the pipeline has improved to over 70%, up from approximately 57% last summer, indicating a healthier demand environment [5] Company Strategy and Development Direction - The company is engaged in a strategic review process to maximize shareholder value and is not issuing formal guidance, but expects modest revenue growth in 2026 and a 200 basis points improvement in Adjusted EBITDA margins [3][22] - A focus on AI strategy spans financial health, patient care, customer service, and internal development, with initiatives aimed at improving claims processing and customer interactions [9][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges challenges in customer retention, particularly in the CBO segment, and has implemented a structured transition model to improve retention rates [6][7] - The company is optimistic about the operational changes and believes it is on the right trajectory for future improvements, despite potential delays in consistent quarterly performance [6][11] Other Important Information - The company has strengthened its financial position through disciplined debt reduction, lowering net debt by approximately $19.5 million year-to-date, and improving its net leverage ratio to 2x [15][16] - The company opened a new Global Capacity Center in Chennai, marking a significant milestone in its global delivery model [8] Q&A Session Summary Question: Can you explain the visibility on revenue growth in relation to new bookings? - Management confirmed that recurring revenues and assumptions of bookings at conversion are key to understanding revenue visibility [25][26] Question: How is customer retention improving in the CBO segment? - Management indicated that retention rates are not yet at desired levels but are showing modest improvement, with a focus on ensuring smooth transitions for customers [27][28] Question: What is the timeline for the strategic review process? - Management stated there is no set timeline for the strategic review, emphasizing the importance of achieving the right outcome over meeting deadlines [30] Question: How should we think about the conversion timing of larger deals in the pipeline? - Management noted that there are no capacity constraints, but the timing of bookings is often dependent on customer readiness [34][35] Question: What synergies exist between Patient Care and Financial Health? - Management highlighted the interconnectivity between the two segments, particularly in serving rural community customers and expanding technology offerings [43][44] Question: What impact will the Rural Health Fund have on customer bases? - Management is actively engaging with hospitals to help them access the $50 billion fund, viewing it as a significant opportunity [70][72] Question: How is AI being leveraged in the business? - Management is cautious about AI implementation, focusing on projects that provide clear ROI and improve customer experience [76][77]

Group 1: Oil Market Dynamics - Markets are reacting positively to news of a potential end to hostilities in Iran, but this overlooks the critical issue of the Strait of Hormuz remaining closed, which is vital for global oil supply [2][3] - Approximately 20% of the world's seaborne oil passes through the Strait daily, and if Iran maintains control, the energy crisis may persist despite a ceasefire [2][3] - The price spread between U.S. WTIC and European Brent crude has reached approximately $15 per barrel, indicating heightened vulnerability for European oil supplies [3] Group 2: Consumer Debt and Auto Loans - A significant portion of car buyers, estimated at 30.5%, are "underwater" on their trade-ins, meaning they owe more on their vehicles than they are worth [7] - The average negative equity on these trade-ins has reached an all-time high of $7,214, with 27% exceeding $10,000 in negative equity [8] - Monthly payments for buyers with negative equity have risen to an average of $916, which is $144 more than those without negative equity [9] Group 3: Private Credit Market Stress - The overall private credit default rate has climbed to 5.8%, the highest since tracking began, with healthcare services leading in defaults [12][13] - Many healthcare providers are struggling due to cuts in Medicaid reimbursement and rising operational costs, leading to interest coverage ratios falling below 1.0x [14] - Consumer products have also seen a significant increase in default rates, rising from 6.1% to 12.8% over the past year, reflecting broader economic stress [16] Group 4: Broader Economic Implications - The financial system is under stress from multiple fronts, including rising oil prices, increasing consumer debt, and a troubled private credit market [22][23] - The upcoming deadline of June 30, 2026, for Business Development Companies and private credit funds to report their results may reveal hidden losses, impacting market perceptions [19][20]

Core Insights - Current market dynamics are influenced by skepticism around AI spending, geopolitical tensions in the Middle East, and stress in private credit markets [1] - Successful investing involves identifying businesses with durable models, strong growth outlooks, and appropriate valuations, particularly in small-cap stocks where inefficiencies exist [2] Company Summaries Phibro Animal Health (PAHC) - Phibro Animal Health operates in the global livestock and animal nutrition markets, benefiting from consistent demand linked to global protein consumption [5] - The company has seen consistent earnings revisions, supporting a Zacks Rank 1 (Strong Buy) rating, indicating improving fundamental momentum [6] - Shares trade at 17.6x forward earnings with a PEG ratio of 0.82, supported by projected EPS growth of 21.5% annually over the next 3–5 years, suggesting growth is not fully priced in [7] Deluxe (DLX) - Deluxe has transitioned from a legacy check-printing company to a diversified provider of payments, data, and marketing solutions, generating revenue from higher-margin digital services [9] - The company holds a Zacks Rank 2 (Buy) as its transformation continues to improve sentiment [10] - Shares trade at 6.7x forward earnings with a PEG ratio of 0.55, indicating a favorable risk/reward setup, and are forming a bull flag pattern, suggesting potential for a breakout [11] Remitly Global (RELY) - Remitly Global facilitates cross-border payments, with revenues expected to grow at nearly 20% annually over the next two years, supported by structural demand [12] - The stock trades at approximately 30x forward earnings, justified by projected EPS growth of 55.3% annually over the next 3–5 years, resulting in a PEG ratio of 0.54 [13] - With a Zacks Rank 2 (Buy), the company is positioned for strong fundamental performance and potential multiple expansion [14] BrightSpring Health Services (BTSG) - BrightSpring Health Services is well-positioned in the healthcare sector, benefiting from demographic trends related to an aging population and rising demand for home and community-based care [15] - The company has a Zacks Rank 1 (Strong Buy) reflecting strong earnings momentum, with projected EPS growth of 47.2% annually over the next 3–5 years, despite trading at 25.8x forward earnings [17] - The stock has shown a steady uptrend, indicating accumulation by long-term investors, which could support continued upward momentum [18] Investment Opportunities - The four companies—PAHC, DLX, RELY, and BTSG—stand out for their earnings momentum, attractive growth-adjusted valuations, and favorable technical setups, presenting differentiated investment opportunities in a crowded market [19]

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, total revenue was approximately $54 million, down 18% from approximately $66 million in 2024, primarily due to lower contributions from healthcare operations [18] - Healthcare operations revenue was approximately $40 million in 2025, compared to approximately $52 million in 2024, with Q4 revenue of approximately $9 million stable compared to $10 million in Q3 [19] - Consolidated gross margin for the full year was approximately 20%, down from approximately 26% in 2024, but showed sequential improvement late in Q4 [21][22] Business Line Data and Key Metrics Changes - The healthcare segment represented about 73% of total revenue in 2025, generating nearly $40 million in sales, all from Florida [9] - A 94% increase in 340B contract revenue was reported in Q4 2025 compared to Q3 2025, driven by new business development and higher margin services [8][19] - E-commerce operations revenue increased to approximately $15 million, up 6% year-over-year, supported by strong demand for satellite connectivity and IoT products [20] Market Data and Key Metrics Changes - The healthcare segment is expanding from Florida to nationwide operations, leveraging a partnership with HealthWarehouse to support customers in all 50 states [4][9] - The e-commerce segment continues to grow, with new sales records set for IoT hardware and recurring high-margin airtime revenue [10] Company Strategy and Development Direction - The company is focused on improving operations, reducing costs, and driving profitability, with a strategic shift towards higher margin, recurring revenue streams [3][25] - The management team emphasizes the importance of maintaining Nasdaq listing as part of growth and expansion plans, which necessitated a reverse stock split [3][28] - The company aims to leverage its partnership with HealthWarehouse to create new revenue streams and expand its healthcare offerings nationally [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about early signs of margin improvement and reduced operating losses expected in the latter half of 2026 [7][25] - The company anticipates continued growth in 340B contract revenue and fulfillment services, with gradual improvement in prescription volumes [20][26] - Management highlighted the importance of cost optimization and strategic refocusing initiatives that are beginning to materialize in financial performance [18][25] Other Important Information - The company reported a significant reduction in operating expenses by approximately 25% to $20 million in 2025, compared to $26 million in 2024 [22] - The company ended the year with nearly $14 million in cash and no meaningful debt, providing flexibility for operations and growth investments [23] Q&A Session Summary Question: Was the reverse split necessary? - Management stated that the reverse split was necessary to maintain Nasdaq listing, as the buyback program expired and was not a viable option [27][28] Question: What are the current plans for the buyback? - Management is considering reinstating the buyback program and will announce details when appropriate [29] Question: What is the status of ongoing lawsuits? - Management is working with counsel to resolve remaining legal matters, with options to proceed to trial or reach a settlement [30]

Company Overview - Healthcare Services Group reported a revenue of $1.84 billion and a net income of $59.06 million for the trailing twelve months (TTM) [5] - The company employs approximately 35,300 individuals and serves around 3,000 healthcare facilities across the United States [5][9] - The stock has experienced a significant one-year price change of 107.6% as of February 26, 2026 [5][4] Transaction Details - Andrew M Brophy, the Chief Accounting Officer, sold 2,490 shares in an open-market transaction valued at approximately $54,000 [1][2] - The shares sold represented 13.7% of Brophy's direct holdings, reducing his position from 18,225 to 15,735 shares [7] - The transaction occurred at a price of around $21.75 per share, with a post-transaction value of approximately $342,000 based on the market close on February 26, 2026 [2][4] Market Context - The transaction took place during a period of robust share price recovery, with the company's shares delivering a total return of 107.6% over the past year [4] - Healthcare Services Group operates a service-based business model, providing outsourced housekeeping, dietary management, and other non-clinical services to healthcare facilities [8][9] - The company's competitive advantage lies in its scale, specialized expertise, and integrated service offerings, which help clients maintain regulatory compliance and operational efficiency [9]

Core Insights - Solventum Corporation (NYSE:SOLV) is attracting significant interest from hedge funds as a recent spin-off company, with CIBC maintaining an Outperformer rating and a price target of $37, citing a cautious but slightly optimistic 2026 forecast [1][3] - Jefferies has reiterated a Buy rating with a price target of $32, noting that while the company slightly exceeded top-line expectations for its fiscal year earnings, adjusted EBITDA was slightly below their forecast but above consensus [4] Company Overview - Solventum Corporation operates in the healthcare sector, focusing on developing, manufacturing, and commercializing solutions to meet critical customer and patient needs both in the US and internationally. The company has three main segments: Medsurg, Dental Solutions, and Health Information Systems [5] Future Outlook - CIBC suggests that management may leverage increased balance sheet capacity for potential mergers and acquisitions to enhance scale, footprint, and service offerings, with such deals possibly occurring in 2026 [3]

Company Overview - Cencora, Inc. (NYSE:COR) is a global pharmaceutical distributor and healthcare services company that supplies medications, medical products, and value-added solutions to pharmacies, hospitals, and long-term care providers to improve patient care and outcomes [5] Acquisition Details - Cencora, Inc. has signed a binding agreement to acquire the retina division of EyeSouth Partners for $1.1 billion [2] - The acquisition will integrate EyeSouth's affiliated retina physicians into COR's Retina Consultants of America, enhancing the company's ability to deliver advanced retina care [2] - This move aims to combine EyeSouth's established clinical expertise with RCA's organizational support, reinforcing Cencora's commitment to community-based ophthalmologists [2] Financial Outlook - Cencora, Inc. reaffirmed its fiscal 2026 adjusted diluted EPS outlook, maintaining a range of $17.45 to $17.75 [3] - The reaffirmation of EPS guidance reflects the company's commitment to delivering consistent results for fiscal year 2026 [4] Leadership Transition - James F. Cleary, the Executive Vice President and Chief Financial Officer, will retire effective June 30, 2026, after a distinguished tenure since 2018 [3][4] - An executive search firm has been retained to identify potential successors, with Cleary assisting in the process to ensure a smooth leadership transition [3]